Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTP-101P in Patients Undergoing Colon Resection
NCT06692179Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MTP-101P in Clostridioides difficile infection (CDI), sponsored by University of Minnesota. Primary endpoints: Engraftment of donor microbiota via determination of alpha and beta diversity at 180 days and Compare baseline microbiome characteristics with changes over time after MTP-101P at 180 days. Started Feb 2025; status: completed.
02
Drugs
MTP-101P
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT06692179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692179.